Efficacy and Safety of Risankizumab in Psoriatic Patients With a History of Malignancy: Real‐World Evidence From a Multicentre Spanish Study

The management of psoriasis in patients with a history of malignancy is challenging. We conducted a multicentre, retrospective study in 17 Spanish centres including 69 patients with moderate‐to‐severe psoriasis and a previous or current malignancy treated with risankizumab; 94.2% of patients showed no recurrence or progression of cancer, while 5.8% experienced progression during therapy. Risankizumab was associated with substantial improvement in psoriasis, with a mean final PASI score of 0.9 ± 1.7 after a mean exposure time of 72 weeks. Tolerance was favourable, and no tumour recurrence was considered treatment‐related. These findings support risankizumab as an effective and safe therapeutic option for this subpopulation.